Short Interest In Jive Software Falls 21%

The most recent short interest data has been released by the NASDAQ for the 05/15/2015 settlement date, which shows a 507,276 share decrease in total short interest for Jive Software Inc (JIVE), to 1,900,200, a decrease of 21.07% since 04/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for JIVE at the 05/15/2015 settlement increased to 647,945, as compared to 268,092 at the 04/30/2015 report. That brought "days to cover" down to 2.93, a 67.34% decrease from the 8.98 days to cover calculated at the previous short interest data release.

The below chart shows the historical "days to cover" for JIVE at previous short interest release dates:

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

Loading+chart++2015+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where JIVE had been shorted as a hedge.

The chart below shows the one year performance of JIVE shares, versus its 200 day moving average. Looking at this chart, JIVE's low point in its 52 week range is $4.88 per share, with $8.75 as the 52 week high point — that compares with a last trade of $5.61.

Jive Software Inc Chart

More from Stocks

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Why Spotify Is the Ultimate Speculative Stock to Buy

Why Spotify Is the Ultimate Speculative Stock to Buy

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data